common.study.topics.clinical

Testing Treatment for Prostate Cancer

common.study.values.description

“Feasibility Trial in Men With Hormone Sensitive Oligometastatic Prostate Cancer”

Patients with hormone sensitive oligometastatic prostate cancer (a?$ 5 metastatic tumours outside of regional pelvic nodes with no more than 3 in any organ system) and no previous treatment to prostate will be treated with intermittent androgen deprivation therapy +/- chemotherapy, stereotactic radiotherapy to all metastases, and either radical prostatectomy or radiotherapy.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Recruiting patients only common.study.methods.is-healthy-yes

Procedure - Radical prostatectomy

Radical prostatectomy

Radiation - HDR (19Gy) or SBRT (35-40Gy)

Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT

participant.views.study.view.additional

participant.views.study.view.scientific-title

Randomized Feasibility Trial of Prostate Radiotherapy vs Prostatectomy in Men With Hormone Sensitive Oligometastatic Prostate Cancer

common.study.values.clinical-trial-id

NCT03301701

participant.views.study.view.id

QeZ1vd